A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05867303
• Other study ID #: RC198-G001
• Status: Recruiting
• Phase: Phase 1
• Start date: June 5, 2023
• Est. completion date: September 30, 2024

Study information

• Verified date: October 2023
• Source: RemeGen Co., Ltd.
• Contact: RemeGen
• Phone: 301-284-1015
• Email: RC198_OncoStudy[@]remegenbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Safety study of RC198 in Subjects with Solid Tumors.

Description:

This is a Phase 1, first-in-human, open-label study to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RC198 in subjects with locally advanced unresectable or metastatic solid tumors for whom standard therapy does not exist, is no longer effective, or is not acceptable.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: September 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.

2. Subjects with locally advanced unresectable or metastatic solid tumors who experience disease progression after standard treatment, or unable to tolerate standard treatment, or refuse standard treatment.

3. At least 1 measurable or evaluable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.

4. Male or female aged = 18 years.

5. ECOG PS score of 0 or 1.

6. Anticipated life expectancy of > 12 weeks.

7. Adequate bone marrow, liver, and renal function defined as:

• Absolute neutrophil count = 1.5× 109/L.

• Absolute lymphocyte count = 500/µL.

• Platelet = 100 × 109/L.

• Hemoglobin = 90 g/L without receiving erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), or granulocyte-macrophage colony stimulating factor (GM-CSF) within 14 days and blood transfusion including red blood cell and platelet transfusion in at least 7 days prior to first dose of investigational product.

• Total bilirubin = 1.5 × ULN or up to 3 × ULN if Gilbert syndrome.

• Alanine aminotransaminase (ALT), aspartate aminotransferase (AST) = 2.5 × ULN when there is no liver metastasis. ALT, AST = 5 × ULN when there is liver metastasis

• Serum creatinine = 1.5 × ULN, or creatinine clearance = 60 mL/min (using Cockcroft-Gault formula); Urine protein < 2 + or 24 hour total urine protein quantity < 1g.

• Activated partial thromboplastin time (APTT) = 1.5× ULN; international normalized ratio (INR) = 1.5.

8. Left ventricular ejection fraction = 50%, as determined by echocardiogram or multiple-gated acquisition (MUGA) scan.

9. Willingness to avoid pregnancy or fathering children based on the criteria below:

1. Women of childbearing potential (WOCBP) who engage in heterosexual intercourse or male subjects whose sexual partners are WOCBP must be able to and agree to use an acceptable, highly effective, double barrier contraception commencing from Screening, during study, and for 6 months after the last dose of investigational product, including:

• Simultaneous use of hormonal contraceptives and must agree to use the same hormonal contraceptive throughout the study, and a condom for the male partner.

• Simultaneous use of intrauterine device (IUD) and condom for the male partner.

• Simultaneous use of diaphragm or cervical cap and condom for the male partner.

• Sterile male partner (vasectomized for at least 6 months prior to first dose of investigational product).

• True abstinence, defined as no sexual intercourse (heterosexual couples). Periodic abstinence and withdrawal are not acceptable methods.

Subjects with same-sex partners (abstinence from penile-vaginal intercourse) or who are abstinent from heterosexual intercourse are not required use contraception when this is their preferred and usual lifestyle.

2. WOCBP must have a negative serum beta human-chorionic gonadotropin (ß-hCG) pregnancy test at Screening and a negative pregnancy test on Day 1 of each cycle. In the event of a positive urine pregnancy test, a serum pregnancy test will be performed for confirmation.

3. Must agree not to donate ova or sperm from Screening, during study, and for 6 months after the last dose of investigational product

4. Must agree not to donate ova or sperm from Screening, during study, and for 6 months after the last dose of investigational product

Exclusion Criteria:

1. Pregnant or lactating.

2. Known to be human immunodeficiency virus (HIV) positive, with active hepatitis (HBV) characterized by elevated levels of HBV ribonucleic acid exceeding the ULN; or active hepatitis C (HCV) with positive HCV ribonucleic acid (RNA); Subjects who are Hepatitis B surface antigen positive or hepatitis B core antibody positive must have undetectable quantitative DNA polymerase chain reaction (PCR).

3. Administration of a live vaccine within 28 days before first dose of investigational and during the study. Note: Seasonal vaccines for influenza or Coronavirus Disease 2019 (COVID-19) vaccines are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.

4. Previous anti-tumor therapies (including surgery, chemotherapy, traditional Chinese medicine, radiotherapy, immunotherapy, biological therapy, hormonal therapy, or investigational agents for cancer treatment) within 4 weeks or within 5 half-lives of anti-tumor agents, whichever is shorter, prior to the first dose of investigational product, or palliative radiotherapy for bone metastases within 2 weeks prior to the first dose of investigational product.

5. Previous adverse reactions resulting from previous anti-tumor therapies, which have not resolved to Grade 0 or 1 according to NCI CTCAE v5.0 (except for alopecia, fatigue, pigmentation and other conditions with no safety risk according to Investigator's opinion) or Baseline within 4 weeks prior to first administration of the investigational product.

6. Experienced prior Grade 3 or higher immune-related toxicity that resulted in permanent drug discontinuation (subjects with prior temporary drug interruptions due to endocrinopathies etc. are eligible).

7. History of therapy with an agent targeting of IL-15 or IL-2.

8. Known hypersensitivity to any excipient contained in the drug formulation of investigational products or supplements to be administered during the study.

9. Uncontrolled diseases including:

1. Uncontrolled infection requiring systematic antibiotics, antivirals or antifungals within 4 weeks prior to first administration of the investigational product.

2. Active infection with COVID-19.

3. Active tuberculosis infection, or still on anti-tuberculosis therapy or received anti-tuberculosis therapy within 1 year prior to first administration of the investigational product.

4. Symptomatic congestive heart failure Grade II-IV (New York Heart Association [NYHA]), symptomatic or uncontrolled arrhythmias, QTc interval > 480 ms or personal or family history of congenital long/short QT syndrome, Severe or unstable angina pectoris, coronary or peripheral artery bypass grafting.

5. Uncontrollable hypertension (systolic blood pressure = 160mmHg or diastolic blood pressure = 100mmHg).

6. Systemic diseases, including diabetes pulmonary fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.

10. History of any arterial thromboembolic event within 6 months prior to the first administration of investigational product, including myocardial infarction, unstable angina pectoris, pulmonary embolism, cerebrovascular stroke, or transient ischemic attack, etc.

11. History of deep vein thrombosis or any other severe thromboembolism within 3 months prior to the first administration of investigational product (implantable venous access port or catheter-derived thrombosis, or superficial venous thrombosis is not considered as "severe" thromboembolism).

12. History of life-threatening bleeding, or Grade 3 or 4 gastrointestinal/variceal bleeding requiring blood transfusion, endoscopy, or surgery, within 3 months prior to the first administration of investigational product.

13. History of other acquired/congenital immunodeficiency diseases.

14. History of organ transplantation allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.

15. A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) within 7 days or other immunosuppressive medication(s) within 14 days of the first dose of investigational product. Subjects using physiologic replacement doses of prednisone at = 10 mg/day, or its equivalent, are eligible.

16. Active autoimmune diseases or history of autoimmune diseases that may relapse.

Note: Subjects with the following diseases are not excluded:

1. Controlled Type I diabetes.

2. Hypothyroidism (provided it is managed with hormone replacement therapy only).

3. Controlled celiac disease.

4. Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia).

5. Any other disease that is not expected to recur in the absence of external triggering factors.

17. History or presence of metastatic brain tumors. Subjects with confirmed brain metastases are eligible for the study provided that they are asymptomatic and radiologically stable without the need for corticosteroid treatment >10 mg or seizure prophylaxis for = 4 weeks prior to first dose of investigational product.

18. Have undergone major surgeries within 4 weeks prior to first dose of investigational product.

19. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage within 7 days prior to first dose of investigational product.

20. Under the treatment of heparin (eg, low molecular weight heparin [LMWH]) or other anticoagulants such as warfarin when administered at a therapeutic dose. Participants using prophylactic doses of heparin (LMWH) are eligible.

21. Diagnosis of any other malignancy within 2 years prior to enrollment, except for the following if adequately treated:

• Local basal cell or squamous cell carcinoma of the skin or related localized.

• Non-melanoma skin cancer.

• Carcinoma in situ of the breast or of the cervix.

• Non-muscle invasive bladder cancer.

• Low grade (Gleason 6 or below) prostate cancer undergoing surveillance with no plans for treatment intervention or previously fully resected.

22. History or presence of uncontrolled mental illness or drug abuse disorder in opinion of the Investigator.

23. The subject is expected to be non-compliant with critical study procedures and is not willing or able to adhere to the study requirements.

24. Subject is deemed inappropriate for this clinical study, or participation in this clinical study is deemed not in the best interest of the subject, at the discretion of the Investigator.

25. Other acute or chronic diseases or abnormal laboratory test that may: increase risk of study participation or investigational product administration, interfere with the interpretation of study results, and disqualify the subject for study participation in the Investigator's judgment.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Colorectal Carcinoma
• Colorectal Neoplasms
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck
• Urothelial Carcinoma

Intervention

Drug:
• RC198 Injection
RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.

Locations

Country	Name	City	State
Australia	ICON Cancer Centre Wesley	Auchenflower	Queensland
Australia	Southern Oncology Clinical Research Unit	Bedford Park	South Australia
Australia	Cabrini Hospital Malvern	Malvern	Victoria
China	Sun Yat-sen Memorial Hospital, Sun Yat-sen University	Guangzhou	Guangdong
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen Co., Ltd.

Countries where clinical trial is conducted

Australia,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD based on number of dose-limiting toxicities (DLTs)	The maximum tolerated dose (MTD) will be assessed based on the number of patients experiencing DLTs, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.	First 4 weeks (28 days) after first dose of study drug
Primary	Determine Recommended Phase 2 Dose (RP2D)	The RP2D may be selected based on the MTD following consultation with the safety monitoring committee with all available data.	Informed consent through 28 days after the last dose of study drug
Primary	Incidence of Adverse Events [Safety and tolerability]	The adverse events occurring or worsening on or after the first dose of the study drug will be recorded.	Informed consent through 28 days after the last dose of study drug
Secondary	Time to maximum serum concentration [Tmax]	Tmax of RC198	Day 1- Day 5 of Week 1 and Week 4, Day 1 of Week 2, Week 3, Week 5 and Week 6 during cycle 1, and Day 1 of Week 1 and Week 4 during subsequent cycles, and EOT (7 days within subject discontinued study drug)
Secondary	Area under the serum concentration verus time curve [AUC]	AUC of RC198	Day 1- Day 5 of Week 1 and Week 4, Day 1 of Week 2, Week 3, Week 5 and Week 6 during cycle 1, and Day 1 of Week 1 and Week 4 during subsequent cycles, and EOT (7 days within subject discontinued study drug)
Secondary	Maximum serum Concentration [Cmax]	Cmax of RC198	Day 1- Day 5 of Week 1 and Week 4, Day 1 of Week 2, Week 3, Week 5 and Week 6 during cycle 1, and Day 1 of Week 1 and Week 4 during subsequent cycles, and EOT (7 days within subject discontinued study drug)
Secondary	Immunogenicity of RC198	Incidence of anti-drug antibody (ADA) against RC198	D1 of W1 and W3 during cycle 1, and D1 of W1 during subsequent cycles, and EOT (7 days within subject discontinued study drug)
Secondary	Object Response Rate (ORR)	ORR will be determined according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. The ORR is defined as the number of patients are either complete response (CR) or partial response (PR), relative to the number of patients belonging to the study of interest	Screening, then every 6 weeks (±7 days) after Day 1 of Cycle 1 Week 1 until 14 days after the last dose of the study drug. Assessed up to 24 months.
Secondary	Disease Control Rate (DCR)	DCR is the proportion of patients with disease control.	Screening, then every 6 weeks (±7 days) after Day 1 of Cycle 1 Week 1 until 14 days after the last dose of the study drug. Assessed up to 24 months.
Secondary	Duration of response (DoR)	DoR is defined, for patients with response, as the time from first documentation of response (CR or PR) to the date of first documentation of progression of disease or death due to any causes whichever occurs first.	From first partial response (PR) or complete response (CR) until disease progression or death, whichever occurs first. Assessed up to 24 months.
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from the date of first administration to the date of the first documentation of progressive disease or death due to any cause, whichever occurs first.	From the first dose until documented disease progression or death, whichever occurs first. Assessed up to 24 months.